ISGLOBAL

go to website

BARCELONA INSTITUTE FOR GLOBAL HEALTH (ISGLOBAL)

At the Barcelona Institute for Global Health (ISGlobal), the Health Public Health Liver Group works daily to put the liver at the centre of health policies, strategies, and interventions, particularly addressing liver conditions among those most vulnerable.

Professor Jeffrey Lazarus and his team are dedicated to addressing the urgent public health challenges posed by liver health around the world. They strive to raise awareness and clarify and develop multidisciplinary approaches to drive innovative public health policies. Their overarching goal is to reduce the high and increasing human and economic burden of prevalent liver diseases, whilst increasing individual quality of life and overall health equity.

The team will spearhead all WP5 activities dedicated to public health, in collaboration with industry partner AstraZeneca. Their responsibilities include assessing gaps in liver screening across Europe and examining the public health and health system implications of liver screening uptake. They will also contribute to communications and dissemination efforts in WP7.

Paula Petrone and her group, the Biomedical Data Science team, are dedicated to developing machine learning algorithms and advanced analytics solutions to make healthcare more efficient and accessible to all. This multidisciplinary team consists of data scientists, epidemiologists, computer vision experts, and a clinician, addressing various topics such as early diagnostic solutions, risk scores for chronic conditions, the discovery of digital biomarkers, patient stratification, and drug discovery aided by machine learning.

This team leads the development of the predictive AI platform that will integrate the biomarker panel and clinical data into a predictive tool for early diagnosis of liver fibrosis (WP3). The goal is to leverage diverse data sources, including patient demographics, medical history, lifestyle factors, and biomarkers, so that AI algorithms can accurately assess individual risk profiles and identify patients who could benefit from therapeutic intervention.

TEAM MEMBERS

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101132901. The JU receives support from the European Union’s Horizon Europe research and innovation programme and EFPIA, COCIR, MedTech Europe, Vaccines Europe and EuropaBio.

Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

Follow us:

Powered by InnovationActa

Privacy Preference Center